Bayer AG (XSWX:BAYN) Total Stockholders Equity: CHF26,254 Mil (As of Mar. 2026)


XSWX:BAYN Bayer AG XSWX:BAYN
35 GF Score
Price CHF47.36
GF Value CHF25.89
Valuation Significantly Overvalued
! 7 Warning Signs
View Full Analysis

What is Bayer AG Total Stockholders Equity?

Bayer AG XSWX:BAYN +3.59% 35 Total Stockholders Equity is CHF26,254 Mil as of Mar. 2026. GuruFocus rates XSWX:BAYN with a GF Score™ of 35/100 and a GF Value™ of CHF25.89 (Significantly Overvalued). The stock has 7 warning signs investors should review.

Bayer AG's Total Stockholders Equity for the quarter that ended in Mar. 2026 was CHF26,254 Mil. It refers to the net assets owned by shareholders. It does not include minority interest.

Total Stockholders Equity is used to calculate Book Value per Share. Bayer AG's Book Value per Share for the quarter that ended in Mar. 2026 was CHF26.72. The ratio of a company's debt over equity can be used to measure how leveraged this company is. Bayer AG's Debt-to-Equity for the quarter that ended in Mar. 2026 was 0.00.

Bayer AG  (XSWX:BAYN) Total Stockholders Equity Explanation

1. Total Stockholders Equity is used to calculate Book Value per Share.

Bayer AG's Book Value per Share for the quarter that ended in Mar. 2026 is

Book Value per Share=(Total Stockholders Equity-Preferred Stock)/Shares Outstanding (EOP)
=(26253.952-0)/982.424
=26.72

2. The ratio of a company's debt over equity can be used to measure how leveraged this company is.

Bayer AG's Debt-to-Equity for the quarter that ended in Mar. 2026 is

Debt-to-Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=(0 + 0) / 26253.952
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Bayer AG Total Stockholders Equity Related Terms

Bayer AG Total Stockholders Equity Historical Data

* Premium members only.

The historical data trend for Bayer AG's Total Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Bayer AG Total Stockholders Equity Chart

Bayer AG Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Stockholders Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 34,363.19 38,263.69 31,052.64 29,789.71 24,212.14

Bayer AG Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Stockholders Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 30,994.78 28,485.45 27,637.38 24,212.14 26,253.95
XSWX:BAYN
35GF Score
Bayer AG XSWX:BAYN
Total Stockholders Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Total Stockholders Equity of CHF26,254 Mil mean?
Bayer AG (XSWX:BAYN) has a Total Stockholders Equity of CHF26,254 Mil as of Mar. 2026. The total amount of shareholder's equity as recorded on a company's balance sheet. View historical data for Bayer AG and its competitors.
Is Bayer AG's Total Stockholders Equity too high?
Bayer AG's current Total Stockholders Equity is CHF26,254 Mil. Overall, Bayer AG has a GF Score™ of 35/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Bayer AG's Total Stockholders Equity compare to LLY and JNJ?
Bayer AG's Total Stockholders Equity of CHF26,254 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Stockholders Equity for a Drug Manufacturers company?
A good Total Stockholders Equity depends on the Drug Manufacturers industry context. However, Total Stockholders Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Stockholders Equity mean?
A high Total Stockholders Equity can signal that a stock is expensive relative to its fundamentals. The total amount of shareholder's equity as recorded on a company's balance sheet. View historical data for Bayer AG and its competitors. Bayer AG's current Total Stockholders Equity is CHF26,254 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bayer AG stock overvalued right now?
Based on GuruFocus' analysis, Bayer AG (XSWX:BAYN) is currently considered Significantly Overvalued. The stock's GF Value™ is CHF25.89, compared to a current price of CHF47.36 — trading 82.9% above its estimated fair value. The current Total Stockholders Equity is CHF26,254 Mil. Bayer AG's overall GF Score™ is 35/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Stockholders Equity calculated?
Total Stockholders Equity is calculated from a company's financial statements. For Bayer AG (XSWX:BAYN), the current Total Stockholders Equity is CHF26,254 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Bayer AG (XSWX:BAYN) Overvalued in 2026?

Based on GuruFocus' analysis, Bayer AG stock appears to be overvalued. The current stock price of CHF47.36 is trading 82.9% above its estimated GF Value™ of CHF25.89. GuruFocus considers Bayer AG to be Significantly Overvalued.

Key valuation signals for XSWX:BAYN:

  • Total Stockholders Equity: CHF26,254 Mil
  • GF Value™: CHF25.89 vs. price of CHF47.36 (82.9% above fair value)
  • GF Score™: 35/100 with 7 warning signs

No single metric tells the full story. See the XSWX:BAYN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Bayer AG Business Description

Address Kaiser-Wilhelm-Allee 1, Leverkusen, NW, DEU, 51368
Bayer is a German healthcare and agriculture conglomerate. Healthcare provides close to half of the company's sales and includes pharmaceutical drugs (about 38% of total sales in 2025) as well as vitamins and other consumer healthcare products (13% of total). The firm's crop science business (47% of total) sells seeds, pesticides, herbicides, and fungicides, which was expanded through its 2018 acquisition of Monsanto.
35GF Score

Get the complete analysis for XSWX:BAYN

Total Stockholders Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

CHF47.36
Price
CHF25.89
GF Value